Allogene Therapeutics (ALLO) Other Non-Current Assets (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Other Non-Current Assets data on file, last reported at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 65.69% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (down 65.69% YoY), and the FY2025 full-year result was $3.6 million, down 64.88% from the prior year.
• Other Non-Current Assets retreated to $3.5 million in Q1 2026, from $3.6 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $10.3 million in Q1 2022 to a low of $3.5 million in Q3 2025.
• A 5-year average of $8.3 million and a median of $9.6 million in 2023 frame the typical range for Other Non-Current Assets.
• Peak annual rise in Other Non-Current Assets reached 99.5% in 2025, while the deepest fall reached 65.87% in 2025.
• Tracing ALLO's Other Non-Current Assets over 5 years: stood at $10.3 million in 2022, then changed by 0.0% to $10.3 million in 2023, then changed by 0.0% to $10.3 million in 2024, then plunged by 64.88% to $3.6 million in 2025, then fell by 2.32% to $3.5 million in 2026.
• Business Quant data shows ALLO's Other Non-Current Assets at $3.5 million in Q1 2026, $3.6 million in Q4 2025, and $3.5 million in Q3 2025.